{"gene":"CSNK2A1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1988,"finding":"The CKA1 gene encodes the 42 kDa alpha catalytic subunit of yeast casein kinase II. Null disruption of CKA1 alone produces no detectable phenotype, indicating functional redundancy with the alpha' subunit encoded by CKA2.","method":"Gene cloning, sequencing, gene replacement/disruption in S. cerevisiae","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct genetic disruption with defined phenotypic readout, replicated by companion CKA2 study","pmids":["3062376"],"is_preprint":false},{"year":1990,"finding":"CKA1 and CKA2 together are essential for viability in S. cerevisiae; simultaneous deletion of both catalytic subunit genes is lethal. Loss of CKII activity causes cells to arrest with increased size, pseudomycelial morphology, and flocculation. Yeast lacking both subunits can be rescued by Drosophila CK2 alpha subunit alone or alpha+beta, demonstrating conservation of CK2 function across evolution.","method":"Gene replacement/disruption double mutant (cka1Δ cka2Δ), phenotypic analysis, cross-species complementation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct genetic epistasis and complementation, replicated across multiple yeast strains","pmids":["2196445"],"is_preprint":false},{"year":1992,"finding":"Casein kinase II forms an alpha2beta2 holoenzyme in vivo. In yeast rescued by Drosophila alpha alone, CK2 activity purifies as a free, catalytically active alpha subunit monomer; in yeast rescued by alpha+beta, it purifies as a mixture of tetrameric holoenzyme and monomeric alpha. Free catalytic subunit (overexpressed 6–18-fold) is not toxic in vivo.","method":"Biochemical purification and characterization of CK2 from rescued yeast strains, activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution, purification, and biochemical characterization in vivo and in vitro","pmids":["1527008"],"is_preprint":false},{"year":1998,"finding":"The CKA1-encoded catalytic subunit has a distinct functional specialization from CKA2: cka1(ts) cka2 strains arrest with a nonpolarized actin cytoskeleton, delocalized chitin deposition, and multinucleate cells, establishing a requirement for CKII (specifically CKA1) in the maintenance of cell polarity in S. cerevisiae.","method":"Temperature-sensitive allele construction, conditional growth arrest, actin and chitin staining, cell morphology analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional allele with defined cellular phenotypes (actin polarization, chitin deposition, nuclear content), two orthogonal readouts","pmids":["9488724"],"is_preprint":false},{"year":1994,"finding":"The human CSNK2A1 gene is located on chromosome 20p13. The gene contains at least 8 exons (covering bases 102–824 of the coding region), and introns contain tandemly arranged Alu repeats.","method":"Genomic library screening, FISH chromosomal localization, exon/intron mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic mapping and chromosomal localization by FISH, single lab","pmids":["8188256"],"is_preprint":false},{"year":1998,"finding":"The complete human CSNK2A1 gene spans 70 kb, consists of 13 exons, has two transcription start sites, and its 5' promoter region shows housekeeping promoter features (no TATA box, CpG island, GC boxes). Reporter gene assay confirmed promoter activity between positions −256 and +144.","method":"Genomic cloning, primer extension, reporter gene assay","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter activity confirmed by reporter assay, primer extension for transcription start sites","pmids":["9503018"],"is_preprint":false},{"year":2011,"finding":"The yeast CKA2 catalytic subunit phosphorylates C-terminal serines of the E2 ubiquitin-conjugating enzyme tmCdc34, and this phosphorylation prevents the synthesis of free polyubiquitin chains, likely by promoting their attachment to substrate.","method":"In vitro kinase assay, genetic epistasis (ubp14Δ, cka2Δ), polyubiquitination assays","journal":"Cell division","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay combined with genetic epistasis, single lab","pmids":["21453497"],"is_preprint":false},{"year":2015,"finding":"Yeast CKA2 is required for H2O2-induced apoptosis and high-temperature stress tolerance by regulating NOS-like-dependent nitric oxide (NO) accumulation; Δcka2 mutants show reduced NOS-like activity and reduced NO after H2O2 or high-temperature stress.","method":"Yeast deletion mutant (Δcka2), NO measurement, NOS-like activity assay, NO donor rescue experiment","journal":"FEMS yeast research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct deletion phenotype with biochemical rescue, single lab","pmids":["26100262"],"is_preprint":false},{"year":2016,"finding":"CSNK2A1 (CK2α) physically binds SIRT6 and phosphorylates it in vitro. Phosphorylation of SIRT6 at Ser338 by CSNK2A1 promotes breast cancer cell proliferation and invasiveness, and is required for nuclear β-catenin localization and upregulation of MMP9, β-catenin, cyclin D1, and NF-κB.","method":"Co-immunoprecipitation, GST pull-down assay, in vitro kinase assay, immunofluorescence, mutant CSNK2A1/SIRT6 transfection, siRNA knockdown","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, reciprocal Co-IP, GST pull-down, and site-directed mutagenesis in one study","pmids":["27746184"],"is_preprint":false},{"year":2021,"finding":"CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 activates the DNA damage repair pathway and confers doxorubicin resistance in osteosarcoma cells. Mutation of the SIRT6 Ser338 phosphorylation site attenuates CSNK2A1-mediated doxorubicin resistance in vivo.","method":"CSNK2A1 overexpression/knockdown, site-directed mutagenesis of SIRT6 Ser338, in vivo tumor models, Western blot","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis at phosphorylation site with in vivo validation, single lab","pmids":["34359939"],"is_preprint":false},{"year":2021,"finding":"CSNK2A1 phosphorylates HMGA2 in a cisplatin-inducible manner. HMGA2 and CSNK2A1 co-localize in the nucleus and interact by co-immunoprecipitation. CX-4945 (CSNK2A1 inhibitor) blocks HMGA2 phosphorylation and sensitizes cervical cancer cells to cisplatin.","method":"Liquid chromatography–tandem mass spectrometry, co-immunoprecipitation, immunofluorescence co-localization, kinase inhibitor treatment","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — LC-MS/MS interaction, Co-IP, co-localization, and pharmacological inhibition, single lab","pmids":["34115920"],"is_preprint":false},{"year":2022,"finding":"In S. pombe, the CK2α catalytic subunit Cka1 phosphorylates transcription cofactor PC4. This phosphorylation downregulates PC4's RNA polymerase II coactivator function; the CK2β regulatory subunit (Ckb1) inhibits this phosphorylation. Mutation of both CK2 consensus serine residues in PC4 abolishes phosphorylation and renders PC4 resistant to CK2α-mediated inactivation.","method":"In vitro phosphorylation assay, in vitro transcription assay, site-directed mutagenesis of PC4 serine residues","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay combined with in vitro transcription and site-directed mutagenesis in one study","pmids":["36012759"],"is_preprint":false},{"year":2022,"finding":"Skeletal muscle-specific conditional knockout of CSNK2A1 in mice results in age-dependent grip strength reduction, impaired neuromuscular transmission, increased regenerating (central-nuclei) fibers, impaired oxidative metabolism with mitochondrial enzyme accumulation, stimulated autophagy, and fragmented neuromuscular junctions with increased synaptic gene expression. Ablation of CSNK2A1 also aberrantly changes protein levels of other CSNK2 subunits.","method":"Skeletal muscle-specific Cre-mediated conditional knockout (HSA-Cre), grip strength, electrophysiology, histology, enzyme activity, Western blot","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with multiple orthogonal phenotypic readouts (strength, NMJ, metabolism, autophagy), single lab","pmids":["36552726"],"is_preprint":false},{"year":2023,"finding":"CSNK2A1 phosphorylates MAX, shifting MAX-MAX homodimers to C-MYC-MAX and β-catenin-MAX heterodimers. These heterodimers increase HMGB1 and IL-6 promoter activities, promoting cholangiocarcinoma cell proliferation, migration, and invasion.","method":"Overexpression, co-immunoprecipitation, promoter activity assays, CK2 inhibitor (CX-4945) treatment, Western blot","journal":"Hepatology communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, promoter assay, and pharmacological inhibition, single lab","pmids":["37347224"],"is_preprint":false},{"year":2023,"finding":"CSNK2A1 competes with AKT1 to bind DUSP2 (dual-specificity phosphatase 2); this competition inhibits CSNK2A1-mediated phosphorylation of AKT1, promoting apoptosis in pancreatic cancer cells in an ERK1/2-independent manner.","method":"Co-immunoprecipitation, competition binding assays, in vitro and in vivo apoptosis assays, knockdown/overexpression","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP-based binding competition with in vitro and in vivo apoptosis readout, single lab","pmids":["37390887"],"is_preprint":false},{"year":2024,"finding":"Cholesterol directly binds to CSNK2A1, augmenting its kinase activity. Activated CSNK2A1 phosphorylates IGF2R at Ser2484, rewiring lipid-driven mitochondrial oxidative phosphorylation and generating reactive oxygen species, creating a positive feedback loop for cholesterol biosynthesis in hepatocellular carcinoma.","method":"Proteomics, phosphoproteomics, direct cholesterol-CSNK2A1 binding assay, kinase activity assay, patient-derived cell lines/organoids/xenografts","journal":"Journal of advanced research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and kinase activity assay with phosphoproteomics, single lab","pmids":["39547439"],"is_preprint":false},{"year":2024,"finding":"OGT mediates O-GlcNAcylation of CSNK2A1, enhancing its protein stability. Knockdown of CSNK2A1 suppresses colorectal cancer cell proliferation, migration, invasion, and EMT; OGT overexpression reverses these effects in a CSNK2A1-dependent manner.","method":"Co-immunoprecipitation, Western blot, immunofluorescence, siRNA knockdown, in vivo tumor model","journal":"Molecular biotechnology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and immunofluorescence for O-GlcNAcylation with functional rescue, single lab","pmids":["38289573"],"is_preprint":false},{"year":2024,"finding":"CSNK2A1 activates autophagy in pancreatic cancer cells, driving gemcitabine resistance. H3K27 acetylation mediates transcriptional regulation of CSNK2A1. The CSNK2A1 inhibitor Silmitasertib inhibits autophagy and restores gemcitabine sensitivity in vitro and in patient-derived xenograft models.","method":"siRNA knockdown, PDX model, autophagy assays, Silmitasertib pharmacological inhibition, bioinformatic analyses","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with defined cellular (autophagy) and in vivo (PDX) phenotype, pharmacological inhibitor corroboration, single lab","pmids":["38290659"],"is_preprint":false},{"year":2025,"finding":"SOX4 transcriptionally upregulates CSNK2A1 by binding its promoter. CSNK2A1 in turn phosphorylates TOP2A, promoting breast cancer cell proliferation, migration, invasion, and tumor growth. Silencing SOX4 reduces CSNK2A1 expression and TOP2A phosphorylation.","method":"Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP), Western blot for phosphorylated TOP2A, siRNA knockdown, in vivo mouse tumor models","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, luciferase reporter, phosphorylation detection, and in vivo validation, single lab","pmids":["39931818"],"is_preprint":false},{"year":2025,"finding":"In S. pombe, the CK2α catalytic subunit Cka1 physically associates with components of RSC chromatin remodeling complex, Pcs1/Mde4 (monopolin) complex, snoRNA-containing ribonucleoproteins, and spliceosomal machinery. In vitro kinase assays show Cka1 directly phosphorylates Pcs1 and Mde4.","method":"RNase-free tandem affinity purification coupled with mass spectrometry, in vitro kinase assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay for substrates, TAP-MS for interactors, single lab","pmids":["40700808"],"is_preprint":false},{"year":2025,"finding":"A CSNK2A1 frameshift variant (c.1020_1021delAG, p.Gly342Glnfs*57) does not impair kinase activity in vitro but results in significantly reduced protein expression relative to wild-type, associated with elevated ubiquitination of the mutant protein.","method":"In vitro kinase assay, Western blot quantification, ubiquitination assay, overexpression of wild-type and mutant plasmids","journal":"Frontiers in genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay with mutant construct and ubiquitination assay, single study","pmids":["41216289"],"is_preprint":false}],"current_model":"CSNK2A1 (CK2α) is the catalytic subunit of the tetrameric serine/threonine kinase CK2 (alpha2beta2 holoenzyme); it is essential for cell viability (together with its paralog CKA2/alpha'), required for cell polarity and neuromuscular junction integrity, and phosphorylates a broad range of substrates including SIRT6 (Ser338), HMGA2, MAX, IGF2R (Ser2484), TOP2A, PC4, AKT1, and monopolin subunits Pcs1/Mde4, thereby regulating DNA damage repair, transcription, Wnt/β-catenin and PI3K-AKT-mTOR signaling, autophagy, and lipid metabolism; its activity is enhanced by direct cholesterol binding and its protein stability is modulated by OGT-mediated O-GlcNAcylation, while its transcription is driven by SOX4 and H3K27 acetylation."},"narrative":{"mechanistic_narrative":"CSNK2A1 encodes the catalytic alpha subunit of the constitutively active, broadly pleiotropic serine/threonine protein kinase casein kinase II (CK2), which assembles in vivo as an alpha2beta2 holoenzyme but retains catalytic activity as a free monomeric alpha subunit [PMID:1527008]. Genetic analysis in yeast established that the catalytic subunit is essential for viability only in conjunction with its paralog (alpha'), with the double deletion being lethal and the alpha subunit alone sufficient to rescue this lethality across species, while the alpha subunit additionally carries a non-redundant role in maintaining cell polarity, actin organization, and nuclear division [PMID:2196445, PMID:9488724]. In mammals, CK2alpha phosphorylates a broad substrate repertoire to control proliferation, transcription, DNA damage repair, and metabolism: it phosphorylates SIRT6 at Ser338 to drive beta-catenin nuclear localization, proliferation, and DNA-repair-linked chemoresistance [PMID:27746184, PMID:34359939]; it phosphorylates the transcriptional regulator MAX to favor C-MYC-MAX and beta-catenin-MAX heterodimers that activate HMGB1 and IL-6 promoters [PMID:37347224]; and it phosphorylates HMGA2 and TOP2A in cancer contexts, with TOP2A phosphorylation downstream of SOX4-driven CSNK2A1 transcription [PMID:34115920, PMID:39931818]. CK2alpha activity is directly enhanced by cholesterol binding, which couples it to phosphorylation of IGF2R at Ser2484 and a lipid-biosynthesis feedback loop, while OGT-mediated O-GlcNAcylation stabilizes the protein and H3K27 acetylation regulates its transcription [PMID:39547439, PMID:38289573, PMID:38290659]. CK2alpha also promotes autophagy to confer chemoresistance and modulates apoptosis through AKT1 phosphorylation that is antagonized by competitive DUSP2 binding [PMID:37390887, PMID:38290659]. In vivo, skeletal-muscle-specific ablation of CSNK2A1 disrupts neuromuscular junction integrity, oxidative metabolism, and autophagy, demonstrating a tissue-level requirement for the kinase [PMID:36552726].","teleology":[{"year":1988,"claim":"Established that CSNK2A1's yeast ortholog encodes a 42 kDa CK2 catalytic alpha subunit whose loss alone is phenotypically silent, defining functional redundancy with a paralogous catalytic subunit.","evidence":"Gene cloning, sequencing, and gene disruption in S. cerevisiae","pmids":["3062376"],"confidence":"High","gaps":["Did not test the double-knockout requirement","No substrate or mammalian function defined"]},{"year":1990,"claim":"Showed the two catalytic subunits are jointly essential for viability and that the function is evolutionarily conserved, since heterologous CK2 alpha rescues the lethal double deletion.","evidence":"cka1Δ cka2Δ double mutant phenotyping and cross-species complementation in yeast","pmids":["2196445"],"confidence":"High","gaps":["Did not resolve which substrates underlie the essential function","Molecular basis of size/morphology arrest unknown"]},{"year":1992,"claim":"Resolved the quaternary biology of CK2 by demonstrating it functions as an alpha2beta2 holoenzyme in vivo but that free catalytic alpha is active and non-toxic, clarifying that the beta subunit is regulatory rather than required for catalysis.","evidence":"Biochemical purification and activity assays from rescued yeast strains","pmids":["1527008"],"confidence":"High","gaps":["Did not define how beta modulates substrate selection in vivo","No structural detail"]},{"year":1998,"claim":"Distinguished a non-redundant role for the alpha catalytic subunit by linking its conditional loss specifically to cell polarity, actin organization, and nuclear division defects.","evidence":"Temperature-sensitive cka1 allele with actin/chitin staining and morphology analysis in yeast","pmids":["9488724"],"confidence":"High","gaps":["Polarity substrates of CK2alpha not identified","Mechanism connecting kinase to actin/chitin unknown"]},{"year":1998,"claim":"Characterized the human CSNK2A1 gene architecture and a housekeeping-type promoter, framing it as a constitutively expressed gene.","evidence":"Genomic cloning, primer extension, reporter assay (consolidated with 1994 FISH mapping)","pmids":["9503018","8188256"],"confidence":"Medium","gaps":["Promoter regulation by specific transcription factors not addressed","No link to expression dynamics in disease"]},{"year":2011,"claim":"Provided a defined substrate-level mechanism by showing CK2 phosphorylation of the E2 enzyme Cdc34 controls polyubiquitin chain handling, connecting CK2 to the ubiquitin system.","evidence":"In vitro kinase assay and genetic epistasis in yeast","pmids":["21453497"],"confidence":"Medium","gaps":["Relevance to mammalian CSNK2A1 not tested","In vivo significance of the chain-attachment effect limited"]},{"year":2016,"claim":"Identified SIRT6 Ser338 as a direct CSNK2A1 phosphosite linking the kinase to Wnt/beta-catenin output and oncogenic proliferation/invasion.","evidence":"Reciprocal Co-IP, GST pull-down, in vitro kinase assay, and site-directed mutagenesis in breast cancer cells","pmids":["27746184"],"confidence":"High","gaps":["Did not establish kinase-substrate stoichiometry in vivo","Generality across cell types limited"]},{"year":2021,"claim":"Extended the SIRT6-Ser338 axis to DNA damage repair and chemoresistance, and added HMGA2 as a cisplatin-inducible substrate, broadening CK2's role in cancer therapy response.","evidence":"Site-directed mutagenesis with in vivo tumor models; LC-MS/MS, Co-IP, and CX-4945 inhibition (two studies)","pmids":["34359939","34115920"],"confidence":"Medium","gaps":["Single-lab findings per substrate","Direct phosphosite on HMGA2 not fully mapped"]},{"year":2022,"claim":"Demonstrated an in vivo tissue requirement by showing skeletal-muscle CSNK2A1 ablation impairs neuromuscular junctions, oxidative metabolism, and autophagy, and that CK2 alpha controls PC4 coactivator activity, tying the kinase to both physiology and transcription regulation.","evidence":"Conditional muscle knockout with electrophysiology/histology in mice; in vitro phosphorylation and transcription assays in S. pombe","pmids":["36552726","36012759"],"confidence":"High","gaps":["Muscle substrates driving NMJ phenotype unknown","PC4 regulation tested in fission yeast, not mammalian cells"]},{"year":2023,"claim":"Expanded CK2's transcriptional and survival signaling roles by defining MAX phosphorylation-driven heterodimer switching and a DUSP2-mediated competitive brake on CK2-AKT1 signaling.","evidence":"Co-IP, promoter assays, competition binding, and apoptosis assays in cancer models","pmids":["37347224","37390887"],"confidence":"Medium","gaps":["MAX phosphosite not mapped","Direct AKT1 phosphosite by CK2 not defined"]},{"year":2024,"claim":"Revealed multilayered regulation of CSNK2A1 itself — cholesterol-binding activation coupled to IGF2R Ser2484 phosphorylation and lipid feedback, OGT O-GlcNAcylation stabilizing the protein, and H3K27ac-driven transcription — linking the kinase to metabolic and epigenetic control of cancer.","evidence":"Direct binding and kinase assays, phosphoproteomics, Co-IP, and PDX models across HCC, CRC, and pancreatic cancer","pmids":["39547439","38289573","38290659"],"confidence":"Medium","gaps":["Each regulatory layer shown in a single cancer context","Cholesterol-binding site on CSNK2A1 not structurally defined"]},{"year":2025,"claim":"Connected upstream transcriptional control (SOX4) to a downstream substrate (TOP2A), mapped fission-yeast interactome including monopolin (Pcs1/Mde4) substrates, and showed a disease-associated frameshift variant destabilizes the protein via ubiquitination without affecting intrinsic kinase activity.","evidence":"ChIP/luciferase and in vivo tumor models; TAP-MS and in vitro kinase assays in S. pombe; variant kinase/ubiquitination assays","pmids":["39931818","40700808","41216289"],"confidence":"Medium","gaps":["TOP2A phosphosite not mapped","Disease phenotype not characterized beyond protein stability","Interactome largely from fission yeast"]},{"year":null,"claim":"How CK2's constitutive, broadly distributed activity is spatially and substrate-selectively targeted in mammalian cells — and which substrates underlie its essential viability and neuromuscular functions — remains unresolved.","evidence":"No single timeline study integrates substrate selection with the in vivo essential/physiological roles","pmids":[],"confidence":"Low","gaps":["No structural model of substrate recognition in the corpus","Essential mammalian substrates undefined","Mechanism coupling holoenzyme assembly to substrate choice unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[8,11,13,15,18,19]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,8,11,19]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[2]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,10,13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,14,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[11,13,18]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[9]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[12,17]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[15]}],"complexes":["CK2 holoenzyme (alpha2beta2)"],"partners":["CSNK2B","SIRT6","HMGA2","MAX","DUSP2","OGT","AKT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P68400","full_name":"Casein kinase II subunit alpha","aliases":[],"length_aa":391,"mass_kda":45.1,"function":"Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine (PubMed:11239457, PubMed:11704824, PubMed:16193064, PubMed:18411307, PubMed:18583988, PubMed:18678890, PubMed:19188443, PubMed:20545769, PubMed:20625391, PubMed:22017874, PubMed:22406621, PubMed:24962073, PubMed:30898438, PubMed:31439799). Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection (PubMed:12631575, PubMed:19387551, PubMed:19387552). May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response (PubMed:12631575, PubMed:19387551, PubMed:19387552). During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage (PubMed:11704824, PubMed:19188443). Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation (PubMed:11239457). Phosphorylates a number of DNA repair proteins in response to DNA damage, such as MDC1, MRE11, RAD9A, RAD51 and HTATSF1, promoting their recruitment to DNA damage sites (PubMed:18411307, PubMed:18583988, PubMed:18678890, PubMed:20545769, PubMed:21482717, PubMed:22325354, PubMed:26811421, PubMed:28512243, PubMed:30898438, PubMed:35597237). Can also negatively regulate apoptosis (PubMed:16193064, PubMed:22184066). Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3 (PubMed:16193064). Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8 (PubMed:16193064). Phosphorylates YY1, protecting YY1 from cleavage by CASP7 during apoptosis (PubMed:22184066). Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552, PubMed:23123191). Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, ATF4, SRF, MAX, JUN, FOS, MYC and MYB (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552, PubMed:23123191). Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function (PubMed:19387550). Mediates sequential phosphorylation of FNIP1, promoting its gradual interaction with Hsp90, leading to activate both kinase and non-kinase client proteins of Hsp90 (PubMed:30699359). Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1 (PubMed:19387549). Acts as an ectokinase that phosphorylates several extracellular proteins (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552). During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552). Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation (PubMed:20625391, PubMed:22406621). Plays an important role in the circadian clock function by phosphorylating BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry (By similarity). Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue (PubMed:24962073). Phosphorylates FMR1, promoting FMR1-dependent formation of a membraneless compartment (PubMed:30765518, PubMed:31439799). May phosphorylate histone H2A on 'Ser-1' (PubMed:38334665)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P68400/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSNK2A1","classification":"Not Classified","n_dependent_lines":85,"n_total_lines":1208,"dependency_fraction":0.07036423841059603},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000101266","cell_line_id":"CID000855","localizations":[{"compartment":"big_aggregates","grade":3},{"compartment":"cytoplasmic","grade":3},{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"NCL","stoichiometry":10.0},{"gene":"CSNK2B","stoichiometry":10.0},{"gene":"CEP170","stoichiometry":4.0},{"gene":"HDAC2","stoichiometry":4.0},{"gene":"POLR2F","stoichiometry":4.0},{"gene":"RBBP4","stoichiometry":4.0},{"gene":"RPL27","stoichiometry":4.0},{"gene":"RPS16","stoichiometry":4.0},{"gene":"KIF1B","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000855","total_profiled":1310},"omim":[{"mim_id":"619818","title":"ELONGATION FACTOR 1; ELOF1","url":"https://www.omim.org/entry/619818"},{"mim_id":"618732","title":"POIRIER-BIENVENU NEURODEVELOPMENTAL SYNDROME; POBINDS","url":"https://www.omim.org/entry/618732"},{"mim_id":"617062","title":"OKUR-CHUNG NEURODEVELOPMENTAL SYNDROME; OCNDS","url":"https://www.omim.org/entry/617062"},{"mim_id":"614854","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 59; LRRC59","url":"https://www.omim.org/entry/614854"},{"mim_id":"613110","title":"BLCAP APOPTOSIS-INDUCING FACTOR; BLCAP","url":"https://www.omim.org/entry/613110"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CSNK2A1"},"hgnc":{"alias_symbol":["Cka1","Cka2"],"prev_symbol":[]},"alphafold":{"accession":"P68400","domains":[{"cath_id":"3.30.200.20","chopping":"24-113","consensus_level":"medium","plddt":96.2103,"start":24,"end":113},{"cath_id":"1.10.510.10","chopping":"120-334","consensus_level":"high","plddt":97.6454,"start":120,"end":334}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P68400","model_url":"https://alphafold.ebi.ac.uk/files/AF-P68400-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P68400-F1-predicted_aligned_error_v6.png","plddt_mean":88.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSNK2A1","jax_strain_url":"https://www.jax.org/strain/search?query=CSNK2A1"},"sequence":{"accession":"P68400","fasta_url":"https://rest.uniprot.org/uniprotkb/P68400.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P68400/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P68400"}},"corpus_meta":[{"pmid":"2196445","id":"PMC_2196445","title":"Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2196445","citation_count":331,"is_preprint":false},{"pmid":"3062376","id":"PMC_3062376","title":"Isolation, sequencing, and disruption of the CKA1 gene encoding the alpha subunit of yeast casein kinase II.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3062376","citation_count":115,"is_preprint":false},{"pmid":"27746184","id":"PMC_27746184","title":"CK2α/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27746184","citation_count":75,"is_preprint":false},{"pmid":"27048600","id":"PMC_27048600","title":"De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features.","date":"2016","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27048600","citation_count":73,"is_preprint":false},{"pmid":"30655572","id":"PMC_30655572","title":"Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures.","date":"2019","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30655572","citation_count":64,"is_preprint":false},{"pmid":"9488724","id":"PMC_9488724","title":"Temperature-sensitive mutations of the CKA1 gene reveal a role for casein kinase II in maintenance of cell polarity in Saccharomyces cerevisiae.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9488724","citation_count":61,"is_preprint":false},{"pmid":"1527008","id":"PMC_1527008","title":"Purification and characterization of casein kinase II (CKII) from delta cka1 delta cka2 Saccharomyces cerevisiae rescued by Drosophila CKII subunits. The free catalytic subunit of casein kinase II is not toxic in vivo.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1527008","citation_count":44,"is_preprint":false},{"pmid":"8188256","id":"PMC_8188256","title":"The human gene (CSNK2A1) coding for the casein kinase II subunit alpha is located on chromosome 20 and contains tandemly arranged Alu repeats.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8188256","citation_count":43,"is_preprint":false},{"pmid":"29383814","id":"PMC_29383814","title":"Extending the phenotype associated with the CSNK2A1-related Okur-Chung syndrome-A clinical study of 11 individuals.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/29383814","citation_count":35,"is_preprint":false},{"pmid":"9503018","id":"PMC_9503018","title":"Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit alpha (CSNK2A1).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9503018","citation_count":31,"is_preprint":false},{"pmid":"31819646","id":"PMC_31819646","title":"CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31819646","citation_count":28,"is_preprint":false},{"pmid":"34038195","id":"PMC_34038195","title":"Identification of novel CSNK2A1 variants and the genotype-phenotype relationship in patients with Okur-Chung neurodevelopmental syndrome: a case report and systematic literature review.","date":"2021","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/34038195","citation_count":24,"is_preprint":false},{"pmid":"37390887","id":"PMC_37390887","title":"DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37390887","citation_count":22,"is_preprint":false},{"pmid":"36271116","id":"PMC_36271116","title":"In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36271116","citation_count":21,"is_preprint":false},{"pmid":"32619668","id":"PMC_32619668","title":"miR-1184 regulates the proliferation and apoptosis of colon cancer cells via targeting CSNK2A1.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/32619668","citation_count":18,"is_preprint":false},{"pmid":"38290659","id":"PMC_38290659","title":"CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38290659","citation_count":17,"is_preprint":false},{"pmid":"34359939","id":"PMC_34359939","title":"CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34359939","citation_count":16,"is_preprint":false},{"pmid":"36213692","id":"PMC_36213692","title":"Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer.","date":"2022","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/36213692","citation_count":16,"is_preprint":false},{"pmid":"37542040","id":"PMC_37542040","title":"The long transcript of lncRNA TMPO-AS1 promotes bone metastases of prostate cancer by regulating the CSNK2A1/DDX3X complex in Wnt/β-catenin signaling.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37542040","citation_count":16,"is_preprint":false},{"pmid":"36310603","id":"PMC_36310603","title":"Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36310603","citation_count":14,"is_preprint":false},{"pmid":"36306106","id":"PMC_36306106","title":"CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition.","date":"2022","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36306106","citation_count":14,"is_preprint":false},{"pmid":"37391010","id":"PMC_37391010","title":"P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37391010","citation_count":11,"is_preprint":false},{"pmid":"31060130","id":"PMC_31060130","title":"[A case of Okur-Chung syndrome caused by CSNK2A1 gene variation and review of literature].","date":"2019","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31060130","citation_count":11,"is_preprint":false},{"pmid":"26100262","id":"PMC_26100262","title":"CKA2 functions in H2O2-induced apoptosis and high-temperature stress tolerance by regulating NO accumulation in yeast.","date":"2015","source":"FEMS yeast research","url":"https://pubmed.ncbi.nlm.nih.gov/26100262","citation_count":9,"is_preprint":false},{"pmid":"32472542","id":"PMC_32472542","title":"[Identification of a novel de novo variant of CSNK2A1 gene in a boy with Okur-Chung neurodevelopmental syndrome].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32472542","citation_count":9,"is_preprint":false},{"pmid":"37347224","id":"PMC_37347224","title":"CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression.","date":"2023","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/37347224","citation_count":8,"is_preprint":false},{"pmid":"34115920","id":"PMC_34115920","title":"CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/34115920","citation_count":8,"is_preprint":false},{"pmid":"21453497","id":"PMC_21453497","title":"The loop-less tmCdc34 E2 mutant defective in polyubiquitination in vitro and in vivo supports yeast growth in a manner dependent on Ubp14 and Cka2.","date":"2011","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/21453497","citation_count":8,"is_preprint":false},{"pmid":"33421986","id":"PMC_33421986","title":"Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.","date":"2020","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33421986","citation_count":8,"is_preprint":false},{"pmid":"39547439","id":"PMC_39547439","title":"Oncogenic cholesterol rewires lipid metabolism in hepatocellular carcinoma via the CSNK2A1-IGF2R Ser2484 axis.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39547439","citation_count":7,"is_preprint":false},{"pmid":"38289573","id":"PMC_38289573","title":"O-GlcNAcylation of CSNK2A1 by OGT is Involved in the Progression of Colorectal Cancer.","date":"2024","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38289573","citation_count":7,"is_preprint":false},{"pmid":"37491870","id":"PMC_37491870","title":"Inherited CSNK2A1 variants in families with Okur-Chung neurodevelopmental syndrome.","date":"2023","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37491870","citation_count":7,"is_preprint":false},{"pmid":"34306196","id":"PMC_34306196","title":"Long non-coding RNA B3GALT5-AS1 contributes to the progression of gastric cancer via interacting with CSNK2A1.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34306196","citation_count":6,"is_preprint":false},{"pmid":"38357263","id":"PMC_38357263","title":"A Case of Okur-Chung Neurodevelopmental Syndrome with a Novel, de novo Variant on the CSNK2A1 Gene in a Turkish Patient.","date":"2023","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/38357263","citation_count":4,"is_preprint":false},{"pmid":"31591414","id":"PMC_31591414","title":"Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31591414","citation_count":3,"is_preprint":false},{"pmid":"39253198","id":"PMC_39253198","title":"Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39253198","citation_count":3,"is_preprint":false},{"pmid":"39497417","id":"PMC_39497417","title":"Expanding the phenotypic spectrum of CSNK2A1-associated Okur-Chung neurodevelopmental syndrome.","date":"2024","source":"HGG advances","url":"https://pubmed.ncbi.nlm.nih.gov/39497417","citation_count":3,"is_preprint":false},{"pmid":"7909530","id":"PMC_7909530","title":"PstI identifies biallelic DNA polymorphism of the human casein kinase 2 alpha gene (CSNK2A1).","date":"1994","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7909530","citation_count":3,"is_preprint":false},{"pmid":"40742416","id":"PMC_40742416","title":"Clinical and molecular results in 15 Turkish patients with Wiedemann-Steiner syndrome: identification of eight novel KMT2A variants and a case of dual molecular diagnosis in the CSNK2A1.","date":"2025","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/40742416","citation_count":2,"is_preprint":false},{"pmid":"36012759","id":"PMC_36012759","title":"The Catalytic Subunit of Schizosaccharomyces pombe CK2 (Cka1) Negatively Regulates RNA Polymerase II Transcription through Phosphorylation of Positive Cofactor 4 (PC4).","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012759","citation_count":2,"is_preprint":false},{"pmid":"36552726","id":"PMC_36552726","title":"In Skeletal Muscle Fibers, Protein Kinase Subunit CSNK2A1/CK2α Is Required for Proper Muscle Homeostasis and Structure and Function of Neuromuscular Junctions.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36552726","citation_count":2,"is_preprint":false},{"pmid":"39931818","id":"PMC_39931818","title":"Novel role of the SOX4/CSNK2A1 axis in regulating TOP2A phosphorylation in breast cancer progression.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39931818","citation_count":2,"is_preprint":false},{"pmid":"40860313","id":"PMC_40860313","title":"Ellagic Acid Mediates the Delay of Dermal Fibroblast Senescence via CSNK2A1.","date":"2025","source":"Clinical, cosmetic and investigational dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/40860313","citation_count":2,"is_preprint":false},{"pmid":"38711237","id":"PMC_38711237","title":"Patient with a heterozygous pathogenic variant in CSNK2A1 gene: A new case to update the Okur-Chung neurodevelopmental syndrome.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/38711237","citation_count":2,"is_preprint":false},{"pmid":"39403680","id":"PMC_39403680","title":"A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence.","date":"2024","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/39403680","citation_count":1,"is_preprint":false},{"pmid":"40700808","id":"PMC_40700808","title":"Exploring the Cka1 kinase interactome: unveiling novel potential regulatory roles of CKII kinase in S. pombe.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/40700808","citation_count":1,"is_preprint":false},{"pmid":"41395761","id":"PMC_41395761","title":"A Case of CSNK2A1 Gene Variant Causing Okur-Chung Syndrome and Analysis of the Clinical Phenotypic Spectrum.","date":"2025","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41395761","citation_count":0,"is_preprint":false},{"pmid":"41216289","id":"PMC_41216289","title":"Identification and functional analysis of a novel CSNK2A1 frameshift variant in stillbirth.","date":"2025","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41216289","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.27.691040","title":"An inositol pyrophosphate interaction screen provides insight into the regulation of plant casein kinase II","date":"2025-11-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.27.691040","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.25.656027","title":"Identifying Molecular Determinants and Therapeutic Targets in Luminal B Breast Cancer: A Systems Biology Approach","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.25.656027","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.01.646642","title":"Altered Protein Phosphorylation in a Novel Midbrain Organoid Model for Bipolar Disorder","date":"2025-04-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.01.646642","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.27.24314463","title":"Identification of genetic variants and their causal association underlying autism spectrum disorder","date":"2024-09-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.27.24314463","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29526,"output_tokens":5066,"usd":0.082284,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13250,"output_tokens":4241,"usd":0.086138,"stage2_stop_reason":"end_turn"},"total_usd":0.168422,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"The CKA1 gene encodes the 42 kDa alpha catalytic subunit of yeast casein kinase II. Null disruption of CKA1 alone produces no detectable phenotype, indicating functional redundancy with the alpha' subunit encoded by CKA2.\",\n      \"method\": \"Gene cloning, sequencing, gene replacement/disruption in S. cerevisiae\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct genetic disruption with defined phenotypic readout, replicated by companion CKA2 study\",\n      \"pmids\": [\"3062376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CKA1 and CKA2 together are essential for viability in S. cerevisiae; simultaneous deletion of both catalytic subunit genes is lethal. Loss of CKII activity causes cells to arrest with increased size, pseudomycelial morphology, and flocculation. Yeast lacking both subunits can be rescued by Drosophila CK2 alpha subunit alone or alpha+beta, demonstrating conservation of CK2 function across evolution.\",\n      \"method\": \"Gene replacement/disruption double mutant (cka1Δ cka2Δ), phenotypic analysis, cross-species complementation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct genetic epistasis and complementation, replicated across multiple yeast strains\",\n      \"pmids\": [\"2196445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Casein kinase II forms an alpha2beta2 holoenzyme in vivo. In yeast rescued by Drosophila alpha alone, CK2 activity purifies as a free, catalytically active alpha subunit monomer; in yeast rescued by alpha+beta, it purifies as a mixture of tetrameric holoenzyme and monomeric alpha. Free catalytic subunit (overexpressed 6–18-fold) is not toxic in vivo.\",\n      \"method\": \"Biochemical purification and characterization of CK2 from rescued yeast strains, activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution, purification, and biochemical characterization in vivo and in vitro\",\n      \"pmids\": [\"1527008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The CKA1-encoded catalytic subunit has a distinct functional specialization from CKA2: cka1(ts) cka2 strains arrest with a nonpolarized actin cytoskeleton, delocalized chitin deposition, and multinucleate cells, establishing a requirement for CKII (specifically CKA1) in the maintenance of cell polarity in S. cerevisiae.\",\n      \"method\": \"Temperature-sensitive allele construction, conditional growth arrest, actin and chitin staining, cell morphology analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional allele with defined cellular phenotypes (actin polarization, chitin deposition, nuclear content), two orthogonal readouts\",\n      \"pmids\": [\"9488724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human CSNK2A1 gene is located on chromosome 20p13. The gene contains at least 8 exons (covering bases 102–824 of the coding region), and introns contain tandemly arranged Alu repeats.\",\n      \"method\": \"Genomic library screening, FISH chromosomal localization, exon/intron mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic mapping and chromosomal localization by FISH, single lab\",\n      \"pmids\": [\"8188256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The complete human CSNK2A1 gene spans 70 kb, consists of 13 exons, has two transcription start sites, and its 5' promoter region shows housekeeping promoter features (no TATA box, CpG island, GC boxes). Reporter gene assay confirmed promoter activity between positions −256 and +144.\",\n      \"method\": \"Genomic cloning, primer extension, reporter gene assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter activity confirmed by reporter assay, primer extension for transcription start sites\",\n      \"pmids\": [\"9503018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The yeast CKA2 catalytic subunit phosphorylates C-terminal serines of the E2 ubiquitin-conjugating enzyme tmCdc34, and this phosphorylation prevents the synthesis of free polyubiquitin chains, likely by promoting their attachment to substrate.\",\n      \"method\": \"In vitro kinase assay, genetic epistasis (ubp14Δ, cka2Δ), polyubiquitination assays\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay combined with genetic epistasis, single lab\",\n      \"pmids\": [\"21453497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Yeast CKA2 is required for H2O2-induced apoptosis and high-temperature stress tolerance by regulating NOS-like-dependent nitric oxide (NO) accumulation; Δcka2 mutants show reduced NOS-like activity and reduced NO after H2O2 or high-temperature stress.\",\n      \"method\": \"Yeast deletion mutant (Δcka2), NO measurement, NOS-like activity assay, NO donor rescue experiment\",\n      \"journal\": \"FEMS yeast research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct deletion phenotype with biochemical rescue, single lab\",\n      \"pmids\": [\"26100262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CSNK2A1 (CK2α) physically binds SIRT6 and phosphorylates it in vitro. Phosphorylation of SIRT6 at Ser338 by CSNK2A1 promotes breast cancer cell proliferation and invasiveness, and is required for nuclear β-catenin localization and upregulation of MMP9, β-catenin, cyclin D1, and NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down assay, in vitro kinase assay, immunofluorescence, mutant CSNK2A1/SIRT6 transfection, siRNA knockdown\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, reciprocal Co-IP, GST pull-down, and site-directed mutagenesis in one study\",\n      \"pmids\": [\"27746184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 activates the DNA damage repair pathway and confers doxorubicin resistance in osteosarcoma cells. Mutation of the SIRT6 Ser338 phosphorylation site attenuates CSNK2A1-mediated doxorubicin resistance in vivo.\",\n      \"method\": \"CSNK2A1 overexpression/knockdown, site-directed mutagenesis of SIRT6 Ser338, in vivo tumor models, Western blot\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis at phosphorylation site with in vivo validation, single lab\",\n      \"pmids\": [\"34359939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2A1 phosphorylates HMGA2 in a cisplatin-inducible manner. HMGA2 and CSNK2A1 co-localize in the nucleus and interact by co-immunoprecipitation. CX-4945 (CSNK2A1 inhibitor) blocks HMGA2 phosphorylation and sensitizes cervical cancer cells to cisplatin.\",\n      \"method\": \"Liquid chromatography–tandem mass spectrometry, co-immunoprecipitation, immunofluorescence co-localization, kinase inhibitor treatment\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — LC-MS/MS interaction, Co-IP, co-localization, and pharmacological inhibition, single lab\",\n      \"pmids\": [\"34115920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In S. pombe, the CK2α catalytic subunit Cka1 phosphorylates transcription cofactor PC4. This phosphorylation downregulates PC4's RNA polymerase II coactivator function; the CK2β regulatory subunit (Ckb1) inhibits this phosphorylation. Mutation of both CK2 consensus serine residues in PC4 abolishes phosphorylation and renders PC4 resistant to CK2α-mediated inactivation.\",\n      \"method\": \"In vitro phosphorylation assay, in vitro transcription assay, site-directed mutagenesis of PC4 serine residues\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay combined with in vitro transcription and site-directed mutagenesis in one study\",\n      \"pmids\": [\"36012759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Skeletal muscle-specific conditional knockout of CSNK2A1 in mice results in age-dependent grip strength reduction, impaired neuromuscular transmission, increased regenerating (central-nuclei) fibers, impaired oxidative metabolism with mitochondrial enzyme accumulation, stimulated autophagy, and fragmented neuromuscular junctions with increased synaptic gene expression. Ablation of CSNK2A1 also aberrantly changes protein levels of other CSNK2 subunits.\",\n      \"method\": \"Skeletal muscle-specific Cre-mediated conditional knockout (HSA-Cre), grip strength, electrophysiology, histology, enzyme activity, Western blot\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with multiple orthogonal phenotypic readouts (strength, NMJ, metabolism, autophagy), single lab\",\n      \"pmids\": [\"36552726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CSNK2A1 phosphorylates MAX, shifting MAX-MAX homodimers to C-MYC-MAX and β-catenin-MAX heterodimers. These heterodimers increase HMGB1 and IL-6 promoter activities, promoting cholangiocarcinoma cell proliferation, migration, and invasion.\",\n      \"method\": \"Overexpression, co-immunoprecipitation, promoter activity assays, CK2 inhibitor (CX-4945) treatment, Western blot\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, promoter assay, and pharmacological inhibition, single lab\",\n      \"pmids\": [\"37347224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CSNK2A1 competes with AKT1 to bind DUSP2 (dual-specificity phosphatase 2); this competition inhibits CSNK2A1-mediated phosphorylation of AKT1, promoting apoptosis in pancreatic cancer cells in an ERK1/2-independent manner.\",\n      \"method\": \"Co-immunoprecipitation, competition binding assays, in vitro and in vivo apoptosis assays, knockdown/overexpression\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP-based binding competition with in vitro and in vivo apoptosis readout, single lab\",\n      \"pmids\": [\"37390887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cholesterol directly binds to CSNK2A1, augmenting its kinase activity. Activated CSNK2A1 phosphorylates IGF2R at Ser2484, rewiring lipid-driven mitochondrial oxidative phosphorylation and generating reactive oxygen species, creating a positive feedback loop for cholesterol biosynthesis in hepatocellular carcinoma.\",\n      \"method\": \"Proteomics, phosphoproteomics, direct cholesterol-CSNK2A1 binding assay, kinase activity assay, patient-derived cell lines/organoids/xenografts\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and kinase activity assay with phosphoproteomics, single lab\",\n      \"pmids\": [\"39547439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OGT mediates O-GlcNAcylation of CSNK2A1, enhancing its protein stability. Knockdown of CSNK2A1 suppresses colorectal cancer cell proliferation, migration, invasion, and EMT; OGT overexpression reverses these effects in a CSNK2A1-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, immunofluorescence, siRNA knockdown, in vivo tumor model\",\n      \"journal\": \"Molecular biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and immunofluorescence for O-GlcNAcylation with functional rescue, single lab\",\n      \"pmids\": [\"38289573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CSNK2A1 activates autophagy in pancreatic cancer cells, driving gemcitabine resistance. H3K27 acetylation mediates transcriptional regulation of CSNK2A1. The CSNK2A1 inhibitor Silmitasertib inhibits autophagy and restores gemcitabine sensitivity in vitro and in patient-derived xenograft models.\",\n      \"method\": \"siRNA knockdown, PDX model, autophagy assays, Silmitasertib pharmacological inhibition, bioinformatic analyses\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with defined cellular (autophagy) and in vivo (PDX) phenotype, pharmacological inhibitor corroboration, single lab\",\n      \"pmids\": [\"38290659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SOX4 transcriptionally upregulates CSNK2A1 by binding its promoter. CSNK2A1 in turn phosphorylates TOP2A, promoting breast cancer cell proliferation, migration, invasion, and tumor growth. Silencing SOX4 reduces CSNK2A1 expression and TOP2A phosphorylation.\",\n      \"method\": \"Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP), Western blot for phosphorylated TOP2A, siRNA knockdown, in vivo mouse tumor models\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, luciferase reporter, phosphorylation detection, and in vivo validation, single lab\",\n      \"pmids\": [\"39931818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In S. pombe, the CK2α catalytic subunit Cka1 physically associates with components of RSC chromatin remodeling complex, Pcs1/Mde4 (monopolin) complex, snoRNA-containing ribonucleoproteins, and spliceosomal machinery. In vitro kinase assays show Cka1 directly phosphorylates Pcs1 and Mde4.\",\n      \"method\": \"RNase-free tandem affinity purification coupled with mass spectrometry, in vitro kinase assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay for substrates, TAP-MS for interactors, single lab\",\n      \"pmids\": [\"40700808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A CSNK2A1 frameshift variant (c.1020_1021delAG, p.Gly342Glnfs*57) does not impair kinase activity in vitro but results in significantly reduced protein expression relative to wild-type, associated with elevated ubiquitination of the mutant protein.\",\n      \"method\": \"In vitro kinase assay, Western blot quantification, ubiquitination assay, overexpression of wild-type and mutant plasmids\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay with mutant construct and ubiquitination assay, single study\",\n      \"pmids\": [\"41216289\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSNK2A1 (CK2α) is the catalytic subunit of the tetrameric serine/threonine kinase CK2 (alpha2beta2 holoenzyme); it is essential for cell viability (together with its paralog CKA2/alpha'), required for cell polarity and neuromuscular junction integrity, and phosphorylates a broad range of substrates including SIRT6 (Ser338), HMGA2, MAX, IGF2R (Ser2484), TOP2A, PC4, AKT1, and monopolin subunits Pcs1/Mde4, thereby regulating DNA damage repair, transcription, Wnt/β-catenin and PI3K-AKT-mTOR signaling, autophagy, and lipid metabolism; its activity is enhanced by direct cholesterol binding and its protein stability is modulated by OGT-mediated O-GlcNAcylation, while its transcription is driven by SOX4 and H3K27 acetylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSNK2A1 encodes the catalytic alpha subunit of the constitutively active, broadly pleiotropic serine/threonine protein kinase casein kinase II (CK2), which assembles in vivo as an alpha2beta2 holoenzyme but retains catalytic activity as a free monomeric alpha subunit [#2]. Genetic analysis in yeast established that the catalytic subunit is essential for viability only in conjunction with its paralog (alpha'), with the double deletion being lethal and the alpha subunit alone sufficient to rescue this lethality across species, while the alpha subunit additionally carries a non-redundant role in maintaining cell polarity, actin organization, and nuclear division [#1, #3]. In mammals, CK2alpha phosphorylates a broad substrate repertoire to control proliferation, transcription, DNA damage repair, and metabolism: it phosphorylates SIRT6 at Ser338 to drive beta-catenin nuclear localization, proliferation, and DNA-repair-linked chemoresistance [#8, #9]; it phosphorylates the transcriptional regulator MAX to favor C-MYC-MAX and beta-catenin-MAX heterodimers that activate HMGB1 and IL-6 promoters [#13]; and it phosphorylates HMGA2 and TOP2A in cancer contexts, with TOP2A phosphorylation downstream of SOX4-driven CSNK2A1 transcription [#10, #18]. CK2alpha activity is directly enhanced by cholesterol binding, which couples it to phosphorylation of IGF2R at Ser2484 and a lipid-biosynthesis feedback loop, while OGT-mediated O-GlcNAcylation stabilizes the protein and H3K27 acetylation regulates its transcription [#15, #16, #17]. CK2alpha also promotes autophagy to confer chemoresistance and modulates apoptosis through AKT1 phosphorylation that is antagonized by competitive DUSP2 binding [#14, #17]. In vivo, skeletal-muscle-specific ablation of CSNK2A1 disrupts neuromuscular junction integrity, oxidative metabolism, and autophagy, demonstrating a tissue-level requirement for the kinase [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established that CSNK2A1's yeast ortholog encodes a 42 kDa CK2 catalytic alpha subunit whose loss alone is phenotypically silent, defining functional redundancy with a paralogous catalytic subunit.\",\n      \"evidence\": \"Gene cloning, sequencing, and gene disruption in S. cerevisiae\",\n      \"pmids\": [\"3062376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test the double-knockout requirement\", \"No substrate or mammalian function defined\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Showed the two catalytic subunits are jointly essential for viability and that the function is evolutionarily conserved, since heterologous CK2 alpha rescues the lethal double deletion.\",\n      \"evidence\": \"cka1\\u0394 cka2\\u0394 double mutant phenotyping and cross-species complementation in yeast\",\n      \"pmids\": [\"2196445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which substrates underlie the essential function\", \"Molecular basis of size/morphology arrest unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Resolved the quaternary biology of CK2 by demonstrating it functions as an alpha2beta2 holoenzyme in vivo but that free catalytic alpha is active and non-toxic, clarifying that the beta subunit is regulatory rather than required for catalysis.\",\n      \"evidence\": \"Biochemical purification and activity assays from rescued yeast strains\",\n      \"pmids\": [\"1527008\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how beta modulates substrate selection in vivo\", \"No structural detail\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Distinguished a non-redundant role for the alpha catalytic subunit by linking its conditional loss specifically to cell polarity, actin organization, and nuclear division defects.\",\n      \"evidence\": \"Temperature-sensitive cka1 allele with actin/chitin staining and morphology analysis in yeast\",\n      \"pmids\": [\"9488724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Polarity substrates of CK2alpha not identified\", \"Mechanism connecting kinase to actin/chitin unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Characterized the human CSNK2A1 gene architecture and a housekeeping-type promoter, framing it as a constitutively expressed gene.\",\n      \"evidence\": \"Genomic cloning, primer extension, reporter assay (consolidated with 1994 FISH mapping)\",\n      \"pmids\": [\"9503018\", \"8188256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter regulation by specific transcription factors not addressed\", \"No link to expression dynamics in disease\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided a defined substrate-level mechanism by showing CK2 phosphorylation of the E2 enzyme Cdc34 controls polyubiquitin chain handling, connecting CK2 to the ubiquitin system.\",\n      \"evidence\": \"In vitro kinase assay and genetic epistasis in yeast\",\n      \"pmids\": [\"21453497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevance to mammalian CSNK2A1 not tested\", \"In vivo significance of the chain-attachment effect limited\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified SIRT6 Ser338 as a direct CSNK2A1 phosphosite linking the kinase to Wnt/beta-catenin output and oncogenic proliferation/invasion.\",\n      \"evidence\": \"Reciprocal Co-IP, GST pull-down, in vitro kinase assay, and site-directed mutagenesis in breast cancer cells\",\n      \"pmids\": [\"27746184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish kinase-substrate stoichiometry in vivo\", \"Generality across cell types limited\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended the SIRT6-Ser338 axis to DNA damage repair and chemoresistance, and added HMGA2 as a cisplatin-inducible substrate, broadening CK2's role in cancer therapy response.\",\n      \"evidence\": \"Site-directed mutagenesis with in vivo tumor models; LC-MS/MS, Co-IP, and CX-4945 inhibition (two studies)\",\n      \"pmids\": [\"34359939\", \"34115920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings per substrate\", \"Direct phosphosite on HMGA2 not fully mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated an in vivo tissue requirement by showing skeletal-muscle CSNK2A1 ablation impairs neuromuscular junctions, oxidative metabolism, and autophagy, and that CK2 alpha controls PC4 coactivator activity, tying the kinase to both physiology and transcription regulation.\",\n      \"evidence\": \"Conditional muscle knockout with electrophysiology/histology in mice; in vitro phosphorylation and transcription assays in S. pombe\",\n      \"pmids\": [\"36552726\", \"36012759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Muscle substrates driving NMJ phenotype unknown\", \"PC4 regulation tested in fission yeast, not mammalian cells\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expanded CK2's transcriptional and survival signaling roles by defining MAX phosphorylation-driven heterodimer switching and a DUSP2-mediated competitive brake on CK2-AKT1 signaling.\",\n      \"evidence\": \"Co-IP, promoter assays, competition binding, and apoptosis assays in cancer models\",\n      \"pmids\": [\"37347224\", \"37390887\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MAX phosphosite not mapped\", \"Direct AKT1 phosphosite by CK2 not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed multilayered regulation of CSNK2A1 itself \\u2014 cholesterol-binding activation coupled to IGF2R Ser2484 phosphorylation and lipid feedback, OGT O-GlcNAcylation stabilizing the protein, and H3K27ac-driven transcription \\u2014 linking the kinase to metabolic and epigenetic control of cancer.\",\n      \"evidence\": \"Direct binding and kinase assays, phosphoproteomics, Co-IP, and PDX models across HCC, CRC, and pancreatic cancer\",\n      \"pmids\": [\"39547439\", \"38289573\", \"38290659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each regulatory layer shown in a single cancer context\", \"Cholesterol-binding site on CSNK2A1 not structurally defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected upstream transcriptional control (SOX4) to a downstream substrate (TOP2A), mapped fission-yeast interactome including monopolin (Pcs1/Mde4) substrates, and showed a disease-associated frameshift variant destabilizes the protein via ubiquitination without affecting intrinsic kinase activity.\",\n      \"evidence\": \"ChIP/luciferase and in vivo tumor models; TAP-MS and in vitro kinase assays in S. pombe; variant kinase/ubiquitination assays\",\n      \"pmids\": [\"39931818\", \"40700808\", \"41216289\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TOP2A phosphosite not mapped\", \"Disease phenotype not characterized beyond protein stability\", \"Interactome largely from fission yeast\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CK2's constitutive, broadly distributed activity is spatially and substrate-selectively targeted in mammalian cells \\u2014 and which substrates underlie its essential viability and neuromuscular functions \\u2014 remains unresolved.\",\n      \"evidence\": \"No single timeline study integrates substrate selection with the in vivo essential/physiological roles\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of substrate recognition in the corpus\", \"Essential mammalian substrates undefined\", \"Mechanism coupling holoenzyme assembly to substrate choice unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [8, 11, 13, 15, 18, 19]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 8, 11, 19]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 10, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 14, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [11, 13, 18]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [12, 17]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [\"CK2 holoenzyme (alpha2beta2)\"],\n    \"partners\": [\"CSNK2B\", \"SIRT6\", \"HMGA2\", \"MAX\", \"DUSP2\", \"OGT\", \"AKT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}